Blackwell Science, LtdREVIEW ARTICLEProspect for a Entamoeba histolytica vaccineReview article Prospect for an Entamoeba histolytica Gal-lectin-based vaccine

Entamoeba histolytica is the aetiological agent of invasive amoebiasis, the third leading parasitic cause of mortality in the world. The disease can be easily cured by chemotherapy; however, prevention, mainly in the form of vaccination, could greatly decrease the incidence of the disease, and possibly help in its eradication. The parasite’s surface galactose and N-acetyl--galactosamine-inhibitable adherence lectin (Gal-lectin) is highly antigenic and is the most promising subunit vaccine candidate. We have generated a Gal-lectin-based DNA vaccine and tested its immunogenicity in mice. Although fur-ther optimization will probably be required, this vaccine could help in the generation of an amoebiasis DNA vaccine for use in humans